CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
27/10/2022
Voltar para busca
Dado oficial do USPTO
NOJECTION
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
43
Atualização mais recente
28/10/2022
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
10/01/2018
Data de registro
07/09/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
07/09/2021
Última transação
28/10/2022
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
18/06/2021
Primeiro uso no comércio
18/06/2021
Código do desenho
4
Tipo de titular
99
Localização do titular
Ringaskiddy, IE
Examinador
KAJUBI, ELIZABETH
Unidade examinadora
L70
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
B. D. (pessoa física)
B. D. (pessoa física)
Biohaven Pharmaceutical Holding Company Limited
Representantes
Andrea Christensen Pfizer Inc.
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medicated and pharmaceutical preparationsboth prescription and over-the-counterfor use in connection with humans and animalsfor the treatment of central nervous system disordersneurologic illnessespsychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemiapost-stroke recoverysevere intracranial atherosclerosiscarotid endarterectomycardiac bypasscerebral vasculitisreversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuriespost- intracranial hemorrhage recoverytraumatic brain injuryspinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseasesAlzheimer's disease (AD)Amyotrophic Lateral Sclerosis (ALS)Huntington's diseaseLewy body dementiafrontotemporal dementiavascular dementiaParkinson's diseasecognitive impairment of agingprogressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathiesglaucomadiabetic retinopathyischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of painopioid sparing analgesiacancer painchronic neuropathic painperipheral neuropathylow back pain in the nature of failed back surgery syndromeradiculopathy in the nature of sciaticadiabetic peripheral neuropathypost-herpetic neuralgiachemotherapy induced neuropathy and other medication induced neuropathiescomplex regional pain syndromefibromyalgiachronic post-operative paincluster thoracotomyphantom limbstump neuroma; pharmaceutical preparations for the treatment of headache and facial painheadachemigrainechronic daily headachecluster headachetrigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseasesbreath holding in Rett syndromedystoniasdysphagiagait abnormalitiesbulbar function in ALSpseudobulbar affectlevodopa-induced dyskinesias in Parkinson's diseaseagitation in ADdisinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsyprecision medicine - adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorderstreatment resistant depressionPost Traumatic Stress Disorder (PTSD) in the nature of hyperarousalsubstance abuse disordersaddiction disordersObsessive Compulsive Disorder (OCD)hoardingtrichotillomaniaeating disordersGeneralized Anxiety Disorder (GAD)adjustment disorderspanic disordermajor depressive episodebipolar disorder in the nature of manic and depressive episodesdysthymiacyclothymiapsychotic disordersschizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disordersspinocerebellar ataxiaFriedriech's ataxiamultisystem atrophyessential tremor; pharmaceutical preparations for the treatment of hearing disorderstinnitusdeliriumsleep disordersparasomniaslearning disordersAttention Deficit Disorder (ADD)Pervasive Developmental Disorders (PDD)Asperger's syndromeautismmenopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancermonotherapy and adjunctive use
Publicações
Histórico de despachos e eventos da marca no USPTO.
43 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
27/10/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
27/10/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
27/10/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
27/10/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
07/09/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
04/08/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
03/08/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
27/06/2021
IUAF
USE AMENDMENT FILED
24/06/2021
EISU
TEAS STATEMENT OF USE RECEIVED
24/06/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
24/12/2020
EX5G
SOU EXTENSION 5 GRANTED
23/12/2020
EXT5
SOU EXTENSION 5 FILED
21/12/2020
EEXT
SOU TEAS EXTENSION RECEIVED
21/12/2020
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
19/08/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/07/2020
EX4G
SOU EXTENSION 4 GRANTED
30/06/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
30/06/2020
EXT4
SOU EXTENSION 4 FILED
17/06/2020
EEXT
SOU TEAS EXTENSION RECEIVED
17/06/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
21/12/2019
EX3G
SOU EXTENSION 3 GRANTED
19/12/2019
EXT3
SOU EXTENSION 3 FILED
19/12/2019
EEXT
SOU TEAS EXTENSION RECEIVED
19/12/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
23/10/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
23/10/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
25/06/2019
EX2G
SOU EXTENSION 2 GRANTED
21/06/2019
EXT2
SOU EXTENSION 2 FILED
21/06/2019
EEXT
SOU TEAS EXTENSION RECEIVED
21/06/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/09/2018
EX1G
SOU EXTENSION 1 GRANTED
10/09/2018
EXT1
SOU EXTENSION 1 FILED
10/09/2018
EEXT
SOU TEAS EXTENSION RECEIVED
10/09/2018
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
26/06/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/05/2018
PUBO
PUBLISHED FOR OPPOSITION
01/05/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/04/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
27/03/2018
DOCK
ASSIGNED TO EXAMINER
27/03/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
24/01/2018
NWAP
NEW APPLICATION ENTERED
13/01/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace NOJECTION ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.